StockNews.AI
NSRX
StockNews.AI
1 min

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

1. Nasus Pharma received Health Canada's No-Objection Letter for NS002. 2. NS002 is an intranasal epinephrine formulation for anaphylaxis treatment. 3. This milestone supports the commencement of the planned Phase 2 clinical study. 4. Intranasal delivery offers benefits over autoinjectors, increasing patient compliance. 5. CEO emphasizes aim to revolutionize anaphylaxis treatment with NS002.

6m saved
Insight
Article

FAQ

Why Bullish?

Regulatory approval often leads to increased investor confidence and potential price gains. Historical trends show similar stocks gain following such milestones.

How important is it?

The approval marks a key step that could significantly impact NSRX's future market position.

Why Long Term?

Regulatory approvals lead to long-term growth opportunities; Phase 2 results will further validate product potential.

Related Companies

AVDLEPZMHGEN
TEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently received a No-Objection Letter from Health Canada, the country’s primary regulatory authority for drugs and medical products, for the Company’s planned Phase 2 clinical study of NS002, its investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data, and manufacturing information, and enables Nasus to advance towards its planned Phase 2 clinical study. "We believe receiving this approval from Health Canada represents an important milestone in our mission to transform anaphylaxis treatment," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "For millions suffering from severe allergies, the fear of needles and inconvenience of carrying autoinjectors leads to poor compliance and potentially life-threatening outcomes. Our Phase 2 study aims to further evaluate how NS002, powered by our proprietary Nasax® technology, can deliver epinephrine effectively while offering patients the ease and convenience of a simple nasal spray. We look forward to initiating the study as soon possible.” About Nasus PharmaNasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or Linkedin. Forward Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements regarding the initiation and outcomes of the Company’s planned Phase 2 clinical studies of NS002; its mission to transform anaphylaxis treatment; the potential for NS002 to address issues related to poor compliance with traditional autoinjectors due to needle fear and inconvenience; the capability of the Company’s proprietary Nasax® technology to deliver epinephrine effectively while offering a simple nasal spray alternative. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Company ContactNasus Pharma Ltd.info@nasuspharma.com Investor ContactArx Investor RelationsNorth American Equities Desknasus@arxhq.com

Related News